Welcome to LookChem.com Sign In|Join Free
  • or
Iminostilbene, also known as 5H-Dibenz[b,f]azepine, is a tricyclic amine with a seven-membered ring. It is a man-made organic heterotricyclic compound consisting of a seven-membered nitrogen heterocycle fused with two benzene rings. Iminostilbene is used as an intermediate or a starting material in the synthesis of various anticonvulsant drugs and has a role as a marine xenobiotic metabolite. It is a yellow to orange-yellow fine powder.

256-96-2

Post Buying Request

256-96-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

256-96-2 Usage

Uses

Used in Pharmaceutical Industry:
Iminostilbene is used as a pharmaceutical intermediate for the production of carbamazepine, oxcarbazepine, and rhodium catalyst ligand. It is a metabolite of carbamazepine, which is primarily used in the treatment of epilepsy and neuropathic pain.
Used in Organic Synthesis:
Iminostilbene serves as a starting material to prepare pharmacologically important dibenzoazepine-pyridazine derivatives and synthesize olefinic multidentate ligand, which is used to prepare Rh(I) complexes.
Used in Antioxidant Applications:
Iminostilbene has good antioxidant effects. N-acetyl iminostilbene, synthesized by incubating iminostilbene with acetic anhydride, demonstrates these antioxidant properties.

Preparation

iminostilbene synthesis: 10,11-Dihydro-5-dibenz(b,f)azepine [Iminodibenzyl, 494-19-9] as raw material was acylated by triphosgene, after bromination by bromine and dehydrobromination, reacted with sodium hydroxide in isopropanol to give Iminostilbene.

Biochem/physiol Actions

2-(Bromomethyl)naphthalene is a fluorescent alkyl bromide. It causes the esterification of free carboxyl groups formed at the surface of polyethylene terephthalate by enzyme hydrolysis. It acts as organic electrophile in the P4S10/acyloin reaction.

Check Digit Verification of cas no

The CAS Registry Mumber 256-96-2 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 2,5 and 6 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 256-96:
(5*2)+(4*5)+(3*6)+(2*9)+(1*6)=72
72 % 10 = 2
So 256-96-2 is a valid CAS Registry Number.
InChI:InChI=1/C14H11N/c1-3-7-13-11(5-1)9-10-12-6-2-4-8-14(12)15-13/h1-10,15H

256-96-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (B21323)  Iminostilbene, 97%   

  • 256-96-2

  • 25g

  • 1342.0CNY

  • Detail
  • Alfa Aesar

  • (B21323)  Iminostilbene, 97%   

  • 256-96-2

  • 100g

  • 3084.0CNY

  • Detail
  • Alfa Aesar

  • (B21323)  Iminostilbene, 97%   

  • 256-96-2

  • 500g

  • 10160.0CNY

  • Detail
  • Sigma-Aldrich

  • (PHR1197)  Iminostilbene;CarbamazepineRelatedCompoundB  pharmaceutical secondary standard; traceable to USP

  • 256-96-2

  • PHR1197-500MG

  • 952.15CNY

  • Detail
  • USP

  • (1093023)  CarbamazepineRelatedCompoundB  United States Pharmacopeia (USP) Reference Standard

  • 256-96-2

  • 1093023-50MG

  • 13,501.80CNY

  • Detail
  • Aldrich

  • (143650)  5H-Dibenz[b,f]azepine  97%

  • 256-96-2

  • 143650-1G

  • 570.96CNY

  • Detail
  • Aldrich

  • (143650)  5H-Dibenz[b,f]azepine  97%

  • 256-96-2

  • 143650-5G

  • 1,987.83CNY

  • Detail

256-96-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 5H-dibenzo[b,f]azepine

1.2 Other means of identification

Product number -
Other names 5H-Dibenzo[b,f]Azepine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:256-96-2 SDS

256-96-2Synthetic route

2-bromostyrene
2039-88-5

2-bromostyrene

2-Chloroaniline
95-51-2

2-Chloroaniline

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With tris-(dibenzylideneacetone)dipalladium(0); sodium t-butanolate; DavePhos In 1,4-dioxane at 110℃; for 6h; Inert atmosphere;99%
N-acetyl iminostilbene
19209-60-0

N-acetyl iminostilbene

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With triethyl borane; sodium hydroxide In tert-butyl methyl ether at 80℃; for 6h; Inert atmosphere; Sealed tube;99%
Stage #1: N-acetyl iminostilbene With Triethoxysilane; sodium triethylborohydride In tert-butyl methyl ether at 80℃; for 6h;
Stage #2: With hydrogenchloride In tert-butyl methyl ether; water at 20℃; for 1h; chemoselective reaction;
99%
Multi-step reaction with 2 steps
1: potassium hydroxide; triethyl borane / tetrahydrofuran / 24 h / 100 °C / Inert atmosphere; Schlenk technique; Sealed tube
2: sodium hydroxide; water / tetrahydrofuran / 1 h / 25 °C / Inert atmosphere; Schlenk technique; Sealed tube
View Scheme
2-(2-phenylethenyl)benzenamine
13066-19-8

2-(2-phenylethenyl)benzenamine

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With phosphoric acid at 100 - 300℃; for 2h; Temperature; Reagent/catalyst; Inert atmosphere; Industrial scale;98.9%
9,10-dihydrodibenzazepine
494-19-9

9,10-dihydrodibenzazepine

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With 1-methyl-2-nitrobenzene; palladium on activated charcoal at 230℃; for 1.5h; Rate constant; Kinetics; Thermodynamic data; var. hydrogen acceptors (also without acceptor); ΔH(excit.), ΔS(excit.); var. temp. and time;98.2%
With oxygen; 2,3-dicyano-5,6-dichloro-p-benzoquinone; sodium nitrite In toluene at 120℃; under 9750.98 Torr; for 8h;24%
Stage #1: 9,10-dihydrodibenzazepine With N-Bromosuccinimide
Stage #2: With pyridine
N-benzyl-5H-dibenzoazepine
78943-58-5

N-benzyl-5H-dibenzoazepine

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With 5%-palladium/activated carbon; hydrogen In methanol at 35 - 40℃; under 1500.15 - 2250.23 Torr; for 5h; Autoclave;97%
5H-N-benzyl-10,11-dihydrobenzazepin-10-one
10464-31-0

5H-N-benzyl-10,11-dihydrobenzazepin-10-one

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With 5%-palladium/activated carbon; hydrogen In methanol at 45 - 50℃; under 7500.75 - 9000.9 Torr; for 5h; Autoclave;94.5%
Multi-step reaction with 2 steps
1: sodium tetrahydroborate; methanol / 4 h / 40 - 45 °C
2: 5%-palladium/activated carbon; hydrogen / methanol / 5 h / 35 - 40 °C / 1500.15 - 2250.23 Torr / Autoclave
View Scheme
5H-dibenz[b,f]azepine-5-carbonylchloride
33948-22-0

5H-dibenz[b,f]azepine-5-carbonylchloride

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
In acetonitrile electrolysis (Et4NClO4, Hg-dropelectrode);92%
10-bromo-dibenz[b,f]azepine
75272-34-3

10-bromo-dibenz[b,f]azepine

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With tetraethylammonium perchlorate In water; N,N-dimethyl-formamide cathode: Hg, working potential: -1.85 V, charge: 2.0-2.1 F/mol, 4-5 h;89%
carbamazepin
298-46-4

carbamazepin

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With tetraethoxy tellurium(IV) In tetrachloromethane for 3h; Heating;85%
With hydrogenchloride In water for 12h; Reagent/catalyst; Darkness;
With carbon dioxide at 160 - 200℃;
1-phenyl-1H-indole
16096-33-6

1-phenyl-1H-indole

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With methanesulfonic acid at 90℃; for 7h; Temperature;83.4%
With polyphosphoric acid at 100℃;67%
With PPA at 75 - 85℃; for 55h; Mechanism; substituent effect discussed;43%
With PPA at 75 - 85℃; for 55h;43%
With methanesulfonic acid; phosphorus pentoxide In toluene at 120℃; for 6h;
1,2-Bis(5H-dibenzazepin-5-yl)ethan-1,2-dion
119872-39-8

1,2-Bis(5H-dibenzazepin-5-yl)ethan-1,2-dion

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
In acetonitrile electrolysis (Et4NClO4, Hg-dropelectrode);80%
10,11-dihydro-5H-dibenzo[b,f]azepin-10-ol
4014-77-1

10,11-dihydro-5H-dibenzo[b,f]azepin-10-ol

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With toluene-4-sulfonic acid In toluene at 25℃; Dean-Stark; Reflux;78%
5-Propa-1,2-dienyl-5H-dibenzo[b,f]azepine
152700-38-4

5-Propa-1,2-dienyl-5H-dibenzo[b,f]azepine

3,5-Dichloro-2,4,6-trimethyl-benzonitrile N-oxide
13456-86-5

3,5-Dichloro-2,4,6-trimethyl-benzonitrile N-oxide

A

dibenzoazepine
256-96-2

dibenzoazepine

B

5-[3-(3,5-Dichloro-2,4,6-trimethyl-phenyl)-4-methylene-4,5-dihydro-isoxazol-5-yl]-5H-dibenzo[b,f]azepine

5-[3-(3,5-Dichloro-2,4,6-trimethyl-phenyl)-4-methylene-4,5-dihydro-isoxazol-5-yl]-5H-dibenzo[b,f]azepine

5-[(5S,6S)-3,9-Bis-(3,5-dichloro-2,4,6-trimethyl-phenyl)-1,7-dioxa-2,8-diaza-spiro[4.4]nona-2,8-dien-6-yl]-5H-dibenzo[b,f]azepine

5-[(5S,6S)-3,9-Bis-(3,5-dichloro-2,4,6-trimethyl-phenyl)-1,7-dioxa-2,8-diaza-spiro[4.4]nona-2,8-dien-6-yl]-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
In tetrachloromethane for 2h; Heating;A 48%
B 30%
C 12%
bromobenzene
108-86-1

bromobenzene

bicyclo[2.2.1]hepta-2,5-diene
121-46-0

bicyclo[2.2.1]hepta-2,5-diene

2-bromoaniline
615-36-1

2-bromoaniline

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With palladium diacetate; caesium carbonate; triphenylphosphine In N,N-dimethyl-formamide at 105 - 130℃; Inert atmosphere;45%
N-benzyl-5H-dibenzoazepine
78943-58-5

N-benzyl-5H-dibenzoazepine

A

9-methyl-acridine
611-64-3

9-methyl-acridine

B

dibenzoazepine
256-96-2

dibenzoazepine

C

pyrrolo<3,2,1-jk>carbazole
208-71-9

pyrrolo<3,2,1-jk>carbazole

D

1,1'-(1,2-ethanediyl)bisbenzene
103-29-7

1,1'-(1,2-ethanediyl)bisbenzene

Conditions
ConditionsYield
at 750℃; under 0.04 Torr; for 0.333333h;A 2%
B 20%
C n/a
D n/a
ethanol
64-17-5

ethanol

5-Azidocarbonyldibenzazepin
116822-14-1

5-Azidocarbonyldibenzazepin

A

acridine
260-94-6

acridine

B

dibenzoazepine
256-96-2

dibenzoazepine

C

1,2-Dihydrobenzimidazo<1,7-a,b><1>benzazepin-1-on
118794-84-6

1,2-Dihydrobenzimidazo<1,7-a,b><1>benzazepin-1-on

D

5-(N-Ethoxycarbonylamino)-dibenzazepin
118794-86-8

5-(N-Ethoxycarbonylamino)-dibenzazepin

Conditions
ConditionsYield
Mechanism; Product distribution; Irradiation; photolyse reactions with different alcohols and CH3CN as educts to different products, also with other reagents; also thermolysis reactions;A n/a
B n/a
C n/a
D 10%
N-methyldibenzazepine
52249-32-8

N-methyldibenzazepine

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With 5,10,15,20-tetraphenyl-21H,23H-porphine iron(lll) chloride; sodium dithionite; air; tetramethyl ammoniumhydroxide In methanol; dichloromethane; water for 0.333333h; Ambient temperature;170 % Chromat.
9,10-dihydrodibenzazepine
494-19-9

9,10-dihydrodibenzazepine

A

acridine
260-94-6

acridine

B

9-methyl-acridine
611-64-3

9-methyl-acridine

C

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
iron(III) oxide at 550℃; for 1h; Product distribution; selectivity, activity of catalysts, variation of catalyst and temperature;A 20.0 % Chromat.
B 5.9 % Chromat.
C 40.8 % Chromat.
manganese(III) oxide; magnesium oxide; potassium carbonate; tin(IV) oxide at 550℃; for 6h; Title compound not separated from byproducts;
diphenylamine-2,2′-dicarboxaldehyde
49579-63-7

diphenylamine-2,2′-dicarboxaldehyde

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
With hydrazine hydrate In acetic acid for 2h; Heating;3.8 g
C34H26N2O2
107185-55-7

C34H26N2O2

A

acridine
260-94-6

acridine

B

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
In ethanol Quantum yield; Irradiation;
C34H28Cl2N2O2
117176-56-4

C34H28Cl2N2O2

A

acridine
260-94-6

acridine

B

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
In ethanol Quantum yield; Irradiation;
9,18-diacetyl-4b,4c,9,13b,13c,18-hexahydro-tetrabenzo[b,f,b',f']cyclobuta[1,2-d;3,4-d']bisazepine
41217-00-9

9,18-diacetyl-4b,4c,9,13b,13c,18-hexahydro-tetrabenzo[b,f,b',f']cyclobuta[1,2-d;3,4-d']bisazepine

A

acridine
260-94-6

acridine

B

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
In ethanol Quantum yield; Irradiation;
9,18-dipropionyl-4b,4c,9,13b,13c,18-hexahydro-tetrabenzo[b,f,b',f']cyclobuta[1,2-d;3,4-d']bisazepine
41217-01-0, 52646-98-7

9,18-dipropionyl-4b,4c,9,13b,13c,18-hexahydro-tetrabenzo[b,f,b',f']cyclobuta[1,2-d;3,4-d']bisazepine

A

acridine
260-94-6

acridine

B

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
In ethanol Quantum yield; Irradiation;
9,18-dibenzoyl-4b,4c,9,13b,13c,18-hexahydro-tetrabenzo[b,f,b',f']cyclobuta[1,2-d;3,4-d']bisazepine
41217-03-2, 52647-00-4

9,18-dibenzoyl-4b,4c,9,13b,13c,18-hexahydro-tetrabenzo[b,f,b',f']cyclobuta[1,2-d;3,4-d']bisazepine

A

acridine
260-94-6

acridine

B

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
In ethanol Quantum yield; Irradiation;
9,10-dihydrodibenzazepine
494-19-9

9,10-dihydrodibenzazepine

1-methyl-2-nitrobenzene
88-72-2

1-methyl-2-nitrobenzene

A

dibenzoazepine
256-96-2

dibenzoazepine

B

o-toluidine
95-53-4

o-toluidine

Conditions
ConditionsYield
palladium on activated charcoal at 230℃; Kinetics; Rate constant; other hydrogen acceptor, var. temp., var. solvents;
9,10-dihydrodibenzazepine
494-19-9

9,10-dihydrodibenzazepine

1,1'-(1,2-ethanediyl)bisbenzene
103-29-7

1,1'-(1,2-ethanediyl)bisbenzene

A

dibenzoazepine
256-96-2

dibenzoazepine

B

(E)-1,2-diphenyl-ethene
103-30-0

(E)-1,2-diphenyl-ethene

Conditions
ConditionsYield
palladium on activated charcoal Kinetics; Rate constant; Thermodynamic data; var. temp, ΔH(excit.), ΔS(excit.);
diphenylamine-2,2'-dicarbonyl chloride
32621-46-8

diphenylamine-2,2'-dicarbonyl chloride

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: H2 / Palladium-Barium sulphate; Quinolin sulphate / xylene / 2.5 h / Heating
2: 3.8 g / Hydrazine hydrate / acetic acid / 2 h / Heating
View Scheme
Vanadox
579-92-0

Vanadox

dibenzoazepine
256-96-2

dibenzoazepine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 11.8 g / Thionyl chloride; Pyridine / 5 h / Heating
2: H2 / Palladium-Barium sulphate; Quinolin sulphate / xylene / 2.5 h / Heating
3: 3.8 g / Hydrazine hydrate / acetic acid / 2 h / Heating
View Scheme
dibenzoazepine
256-96-2

dibenzoazepine

benzyl bromide
100-39-0

benzyl bromide

N-benzyl-5H-dibenzoazepine
78943-58-5

N-benzyl-5H-dibenzoazepine

Conditions
ConditionsYield
With sodium hydroxide; tetra(n-butyl)ammonium hydrogensulfate In dichloromethane; water for 48h;100%
In dimethyl sulfoxide for 1.5h;35%
With sodium hydroxide; Aliquat 336 In dichloromethane at 20℃;32%
dibenzoazepine
256-96-2

dibenzoazepine

acetyl chloride
75-36-5

acetyl chloride

N-acetyl iminostilbene
19209-60-0

N-acetyl iminostilbene

Conditions
ConditionsYield
Stage #1: dibenzoazepine With sodium hydride In N,N-dimethyl-formamide; mineral oil Inert atmosphere;
Stage #2: acetyl chloride In N,N-dimethyl-formamide; mineral oil at 23℃; for 1h; Inert atmosphere;
100%
In toluene at 80℃; for 2h; Inert atmosphere;93%
In toluene at 80℃; for 2h; Inert atmosphere;93%
dibenzoazepine
256-96-2

dibenzoazepine

allyl bromide
106-95-6

allyl bromide

5-allyl-5H-dibenzo[b,f]azepine
74074-19-4

5-allyl-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With sodium hydroxide; tetra(n-butyl)ammonium hydrogensulfate In dichloromethane; water for 48h;100%
Stage #1: dibenzoazepine With tetrabutylammomium bromide; sodium hydroxide In water; toluene at 20℃; for 0.25h;
Stage #2: allyl bromide In water; toluene at 20 - 55℃; for 4h;
95%
In dimethyl sulfoxide for 1.5h;46%
With potassium carbonate In methanol for 5h; Heating;
With sodium hydroxide; N,N-didecyl-N,N-dimethylammonium bromide In toluene at 55℃; for 4h;
dibenzoazepine
256-96-2

dibenzoazepine

chloroacetyl chloride
79-04-9

chloroacetyl chloride

2-chloro-1-(5H-dibenzo[b,f]azepin-5-yl)ethan-1-one
41216-96-0

2-chloro-1-(5H-dibenzo[b,f]azepin-5-yl)ethan-1-one

Conditions
ConditionsYield
With N,N-dimethyl-aniline In tetrahydrofuran for 1h; Heating;100%
In benzene for 3h; Heating;94.3%
In toluene at 90℃; for 4h; Inert atmosphere;88%
With pyridine In acetonitrile at 20℃; for 24h; Acylation;80%
In toluene for 12h; Heating;
dibenzoazepine
256-96-2

dibenzoazepine

3-bromo-9H-carbazole
1592-95-6

3-bromo-9H-carbazole

N-[3-(9H-carbazolyl)]iminostilbene

N-[3-(9H-carbazolyl)]iminostilbene

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 80℃; for 16h; Inert atmosphere;100%
dibenzoazepine
256-96-2

dibenzoazepine

tert-butyl 6-oxohexylcarbamate
80860-42-0

tert-butyl 6-oxohexylcarbamate

(Z)-tert-Butyl 6-(5H-dibenzo[b,f]azepin-5-yl)hexylcarbamate
960129-50-4

(Z)-tert-Butyl 6-(5H-dibenzo[b,f]azepin-5-yl)hexylcarbamate

Conditions
ConditionsYield
With dibutyltin chloride; HSiPh3 In tetrahydrofuran at 20℃;99%
dibenzoazepine
256-96-2

dibenzoazepine

mesitylene-2-carboxylic acid chloride
938-18-1

mesitylene-2-carboxylic acid chloride

5-(2,4,6-trimethylbenzoyl)-5H-dibenz[b,f]azepine

5-(2,4,6-trimethylbenzoyl)-5H-dibenz[b,f]azepine

Conditions
ConditionsYield
Stage #1: dibenzoazepine With potassium hexamethylsilazane In tetrahydrofuran at 0℃; Inert atmosphere;
Stage #2: mesitylene-2-carboxylic acid chloride In tetrahydrofuran at 0 - 23℃; for 1h; Inert atmosphere;
99%
bromobenzene
108-86-1

bromobenzene

dibenzoazepine
256-96-2

dibenzoazepine

N-phenyldibenzazepine
78943-59-6

N-phenyldibenzazepine

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;99%
With nickel(II) oxide; potassium tert-butylate; triphenylphosphine In tetrahydrofuran at 100℃; for 24h; Inert atmosphere; Sealed tube; Green chemistry;85%
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Reagent/catalyst; Inert atmosphere;71%
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Solvent; Sealed tube; Inert atmosphere;71%
With tris(dibenzylideneacetone)dipalladium(0) chloroform complex; tri-tert-butyl phosphine; sodium t-butanolate In toluene at 110℃; Buchwald-Hartwig Coupling; Inert atmosphere;
dibenzoazepine
256-96-2

dibenzoazepine

2-Bromobiphenyl
2052-07-5

2-Bromobiphenyl

N-(2-biphenyl)iminostilbene

N-(2-biphenyl)iminostilbene

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;99%
dibenzoazepine
256-96-2

dibenzoazepine

o-trifluoromethylphenyl bromide
392-83-6

o-trifluoromethylphenyl bromide

N-[2-(trifluoromethyl)phenyl]iminostilbene

N-[2-(trifluoromethyl)phenyl]iminostilbene

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane for 16h; Inert atmosphere;99%
dibenzoazepine
256-96-2

dibenzoazepine

1-Bromo-4-fluorobenzene
460-00-4

1-Bromo-4-fluorobenzene

5-(4-fluorophenyl)-5H-dibenzo[b,f]azepine
1414856-37-3

5-(4-fluorophenyl)-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;99%
5-bromo-1H-indole
10075-50-0

5-bromo-1H-indole

dibenzoazepine
256-96-2

dibenzoazepine

N-(3-indazolyl)iminostilbene

N-(3-indazolyl)iminostilbene

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 80℃; for 16h; Inert atmosphere;99%
dibenzoazepine
256-96-2

dibenzoazepine

hexanoic acid
142-62-1

hexanoic acid

C20H23N*ClH

C20H23N*ClH

Conditions
ConditionsYield
Stage #1: hexanoic acid With sodium tetrahydroborate In toluene at 0 - 5℃;
Stage #2: dibenzoazepine With sodium tetrahydroborate In toluene at 25 - 80℃; for 4h;
Stage #3: With hydrogenchloride In water; isopropyl alcohol
99%
dibenzoazepine
256-96-2

dibenzoazepine

2,2-dichloropropane
594-20-7

2,2-dichloropropane

C17H17N

C17H17N

Conditions
ConditionsYield
Stage #1: dibenzoazepine With C29H35Br2CoN3; zinc dibromide; zinc In tetrahydrofuran at 22℃; for 0.25h; Simmons-Smith Cyclopropanation; Inert atmosphere; Glovebox;
Stage #2: 2,2-dichloropropane In tetrahydrofuran at 22℃; for 24h; Simmons-Smith Cyclopropanation; Inert atmosphere; Glovebox; regioselective reaction;
99%
dibenzoazepine
256-96-2

dibenzoazepine

5-(cyano)dibenzothiophenium triflate

5-(cyano)dibenzothiophenium triflate

5-cyanodibenzazepine
42787-75-7

5-cyanodibenzazepine

Conditions
ConditionsYield
With caesium carbonate In dichloromethane at 20℃; for 6h; Inert atmosphere;99%
dibenzoazepine
256-96-2

dibenzoazepine

sodium isocyanate
917-61-3

sodium isocyanate

carbamazepin
298-46-4

carbamazepin

Conditions
ConditionsYield
In water; acetic acid at 15 - 60℃; for 4h; Product distribution / selectivity;98.8%
In acetic acid at 18 - 60℃; for 5h; Product distribution / selectivity;95.9%
In ethanol; acetic acid at 60 - 80℃; for 1.5h; Product distribution / selectivity;93.7%
dibenzoazepine
256-96-2

dibenzoazepine

benzoyl chloride
98-88-4

benzoyl chloride

(5H-dibenzo[b,f]azepin-5-yl)(phenyl)methanone
41216-97-1

(5H-dibenzo[b,f]azepin-5-yl)(phenyl)methanone

Conditions
ConditionsYield
Stage #1: dibenzoazepine With n-butyllithium In tetrahydrofuran; hexane at 20℃; for 0.25h;
Stage #2: benzoyl chloride In dichloromethane at 20℃; Further stages.;
98%
In benzene96%
In benzene for 3h; Heating;85.6%
dibenzoazepine
256-96-2

dibenzoazepine

2,4,6-trichlorobenzoyl chloride
4136-95-2

2,4,6-trichlorobenzoyl chloride

5-(2,4,6-trichlorobenzoyl)-5H-dibenz[b,f]azepine

5-(2,4,6-trichlorobenzoyl)-5H-dibenz[b,f]azepine

Conditions
ConditionsYield
Stage #1: dibenzoazepine With potassium hexamethylsilazane In tetrahydrofuran at 0℃; Inert atmosphere;
Stage #2: 2,4,6-trichlorobenzoyl chloride In tetrahydrofuran at 0 - 23℃; for 1h; Inert atmosphere;
98%
dibenzoazepine
256-96-2

dibenzoazepine

2-Bromo-m-xylene
576-22-7

2-Bromo-m-xylene

N-(2,6-dimethylphenyl)iminostilbene

N-(2,6-dimethylphenyl)iminostilbene

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;98%
dibenzoazepine
256-96-2

dibenzoazepine

chlorobenzene
108-90-7

chlorobenzene

N-phenyldibenzazepine
78943-59-6

N-phenyldibenzazepine

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;98%
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Inert atmosphere;72%
With potassium tert-butylate; copper(II) oxide In dimethyl sulfoxide at 80℃; for 18h; Solvent; Sealed tube; Inert atmosphere;72%
dibenzoazepine
256-96-2

dibenzoazepine

2-methylphenyl bromide
95-46-5

2-methylphenyl bromide

5-(o-tolyl)-5H-dibenzo[b,f]azepine
152019-98-2

5-(o-tolyl)-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;98%
dibenzoazepine
256-96-2

dibenzoazepine

9-bromophenanthrene
573-17-1

9-bromophenanthrene

N-(9-phenanthryl)iminostilbene

N-(9-phenanthryl)iminostilbene

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;98%
1-bromo-4-methoxy-benzene
104-92-7

1-bromo-4-methoxy-benzene

dibenzoazepine
256-96-2

dibenzoazepine

5-(4-methoxyphenyl)-5H-dibenzo[b,f]azepine
152019-82-4

5-(4-methoxyphenyl)-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;98%
2-bromo-1-benzothiophene
5394-13-8

2-bromo-1-benzothiophene

dibenzoazepine
256-96-2

dibenzoazepine

N-(2-benzothiophenyl)iminostilbene

N-(2-benzothiophenyl)iminostilbene

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 80℃; for 16h; Inert atmosphere;98%
2-chloropyridine
109-09-1

2-chloropyridine

dibenzoazepine
256-96-2

dibenzoazepine

5-(pyridin-2-yl)-5H-dibenzo[b,f]azepine
1385022-02-5

5-(pyridin-2-yl)-5H-dibenzo[b,f]azepine

Conditions
ConditionsYield
With tris-(dibenzylideneacetone)dipalladium(0); 1-methyl-2-(2-(dicyclohexylphosphino)phenyl)-1H-benzoimidazole; sodium t-butanolate In toluene at 20 - 135℃; for 24h; Buchwald-Hartwig reaction; Inert atmosphere;97%
dibenzoazepine
256-96-2

dibenzoazepine

2,6-dimethyl-1-chlorobenzene
6781-98-2

2,6-dimethyl-1-chlorobenzene

N-(2,6-dimethylphenyl)iminostilbene

N-(2,6-dimethylphenyl)iminostilbene

Conditions
ConditionsYield
With C30H43O2P*C13H12N(1-)*CH3O3S(1-)*Pd(2+); lithium hexamethyldisilazane In 1,4-dioxane at 100℃; for 16h; Inert atmosphere;97%

256-96-2Relevant academic research and scientific papers

Stability indicating spectrophotometric methods for quantitative determination of carbamazepine and its degradation product, iminostilbene, in pure form and pharmaceutical formulations

, ()

A stressed study on the stability and degradation behavior under ICH forced degradation conditions of most widely used antiepileptic drug; carbamazepine (CMZ) is presented in this work. The research also includes studying spectrophotometric nature of CMZ and assaying it with mostly used spectrophotometric techniques. Six simple and sensitive spectrophotometric methods are introduced as stability indicating methods for quantitative determination of CMZ and its degradation product, one of its reported potential impurities; iminostilbene (IMS). Dual wavelength is method I where two wavelengths (215 and 270 nm for CMZ and 258 and 307 nm for IMS) were chosen for each component while absorbance difference is zero for the second one. Method II is isoabsorptive point method where the absorbance of CMZ at A225 nm was measured in the range of 0.5–20 μg mL?1. Method III is second derivative method which allows simultaneous determination of CMZ at 247 nm and IMS at 273 nm without any interference. Method IV based on measuring the peak amplitude of first derivative of ratio spectra (1DD) at 280.5 and 253 nm for determination of CMZ and IMS, respectively. Method V is mean centering of the ratio spectra with good linearity for CMZ and IMS over 200–330 nm. Ratio difference method is method VI where good linearity was achieved for determination of CMZ and IMS by measuring differences in the amplitude of ratio spectra at 285, 258 nm and 258, 285 nm, respectively. The proposed methods show successful application in CMZ's pharmaceutical formulations.

High temperature polymorphic conversion of carbamazepine in supercritical CO2: A way to obtain pure polymorph I

Oparin, Roman D.,Vaksler, Yevhenii A.,Krestyaninov, Michael A.,Idrissi, Abdenacer,Kiselev, Michael G.

, (2021)

In this work, we studied the high-temperature polymorphic conversion of carbamazepine (CBZ) in a high-density supercritical CO2 (scCO2) medium in the temperature range of 110–200°C. In order to understand the mechanism of transformation we performed a detailed IR analysis of the supercritical fluid (SCF) phase being in permanent contact with an excess of CBZ. We studied the conformational equilibrium of CBZ molecules in scCO2 phase under isochoric heating conditions. Three temperature ranges, where different types of CBZ–scCO2 equilibria are realized, were considered: i. ?CBZ solid – SCF solution?; ii. phase transition region related to the melting of CBZ in high-density scCO2; iii. ?CBZ melt – SCF solution?. An analysis of the IR spectroscopy data on CBZ dissolved in the scCO2 phase obtained for the third temperature range shows that when ?CBZ melt – SCF solution? equilibrium exists, the scCO2 phase contains only one CBZ conformer. Relying on this finding, we hypothesized that it is possible to obtain pure CBZ polymorph I by the crystallization from CBZ solution in scCO2. This statement has been proven by the micro-Raman analysis of the crystalline substance being obtained from such fluid solution.

Method for synthesizing iminostilbene

-

Paragraph 0018-0033, (2021/03/11)

The invention discloses a method for synthesizing iminostilbene, which comprises the following steps: by using 1-phenylindole as a starting raw material, carrying out intramolecular rearrangement reaction on 1-phenylindole under the action of a composite acidic catalytic system to generate iminostilbene; wherein the composite acidic catalytic system is formed by mixing a phosphorus-containing acidic substance and a sulfur-containing acidic substance, the phosphorus-containing acidic substance is one or more of polyphosphoric acid, phosphoric acid and phosphorus pentoxide, and the sulfur-containing acidic substance is one or more of sulfuric acid, methanesulfonic acid and p-toluenesulfonic acid. The phosphorus-containing acidic substance and sulfur-containing acidic substance are used together to form the composite acidic catalytic system, the catalytic system is used in a reaction for catalytic synthesis of iminostilbene, corresponding reaction conditions are optimized, reaction time is shortened, side reactions are reduced, and therefore the method has the advantages of being high in product yield, short in reaction time and the like. The highest yield of the product reaches 83.4%, the purity is 99%, and a good technical effect is achieved.

Combined KOH/BEt3Catalyst for Selective Deaminative Hydroboration of Aromatic Carboxamides for Construction of Luminophores

Li, Jinshan,Wang, Jiali,Yang, Jianguo,Yao, Wubing,Zhong, Aiguo

, p. 8086 - 8090 (2020/11/03)

The selective catalytic C-N bond cleavage of amides into value-added amine products is a desirable but challenging transformation. Molecules containing iminodibenzyl motifs are prevalent in pharmaceutical molecules and functional materials. Here we established a combined KOH/BEt3 catalyst for deaminative hydroboration of acyl-iminodibenzyl derivatives, including nonheterocyclic carboxamides, to the corresponding amines. This novel transition-metal-free methodology was also applied to the construction of Clomipramine and luminophores.

Hydride-catalyzed selectively reductive cleavage of unactivated tertiary amides using hydrosilane

Yao, Wubing,Li, Rongrong,Yang, Jianguo,Hao, Feiyue

, p. 3874 - 3878 (2019/08/07)

The first hydride-catalyzed reductive cleavage of various unactivated tertiary amides, including the biologically active aryl-phenazine carboxamides and the challenging non-heterocyclic carbonyl functions, using low-cost hydrosilane as a reducing reagent has been developed. The novel catalyst system exhibits high efficiency and exclusive selectivity, providing the desired amines in useful to excellent yields under mild conditions. Overall, this transition metal-free process may offer a versatile alternative to currently employed expensive reducing reagents, high-pressure hydrogen or metal systems for the selective reductive cleavage of amides.

Chemical synthesis, spectroscopic studies, chemical reactivity properties and bioactivity scores of an azepin-based molecule

Kollur, Shiva Prasad,Castro, Joaquín Ortega,Frau, Juan,Glossman-Mitnik, Daniel

, p. 300 - 306 (2018/12/13)

Azepines derived molecules are of great interest because of their multi-drug like properties and thus advantageous in biomedical field. Herein, a novel route is described for the synthesis of an azepine-based molecule, 10,11-Dibromo-10,11-dihydro- 5H-dibenzo[b,f]azepine-5-carbonyl chloride (DACC) by using dibutyltin dilaurate (DBTDL) as catalyst. The structure of DACC was elucidated by using FT-IR, NMR, and mass spectroscopic techniques. Several density functionals were considered for the study of the molecular properties of the synthesized compound. The global and local reactivity descriptors were estimated by using Conceptual Density Functional Theory (CDFT). The active sites suitable for the nucleophilic and electrophilic attacks were selected by linking them with the Fukui indices, Parr functions and condensed Dual Descriptor Δf(r). Finally, the bioactivity scores for the studied molecule were predicted through different methodologies.

Intermediate compound, carbamazepine and derivative thereof as well as preparation method of oxcarbazepine and derivative thereof

-

Paragraph 0134; 0135, (2019/12/25)

The invention provides an intermediate compound, carbamazepine and a derivative thereof as well as a preparation method of oxcarbazepine and a derivative thereof. 2-substituted aminophenylacetate or 2-substituted aminophenylacetonitrile and 2-halobenzonitrile are used as raw materials, substitution reaction, intramolecular condensation reaction, hydrolysis and hydrochloric acid acidification are carried out to obtain the oxcarbazepine and the derivative 5-substituent-10-oxa-10, 11-dihydro-5H-dibenzo [b, f] aza thereof, and the derivative of the oxcarbazepine can be used as a raw material to prepare the carbamazepine and the derivative 5-substituted iminostilbene thereof, an intermediate compound iminostilbene and intermediate compounds 5-substituted-10-methoxyiminostilbene and 10-methoxyiminostilbene. The raw materials used in the method are cheap and easy to obtain, and the cost is low; the preparation method is simple, conditions are easy to realize, the method is simple, convenientand safe to operate, and the process flow is short; the production amount of three wastes is small, and thus, the method is environmentally friendly; and a target product has high yield and purity, and is suitable for industrial production.

A disubstituted amide derivatives decarbonylation hydrogenation green new method (by machine translation)

-

Paragraph 0038; 0039; 0040; 0041, (2018/02/04)

The invention relates to a high efficiency, high selectivity of the disubstituted amide derivatives of decarbonylation hydrogenation reaction green new method. For the first time to the metallic compound triethylborane as catalyst, under mild conditions can be conveniently catalytic N, N - di-aryl substituted amide and its derivative and cheap and easy to obtain organic silicon reagent selective preparation of secondary organic amine product. Compared with the traditional method, the new method generally has the wide substrate universality, functional group compatibility outstanding, simple operation and the like. For the first time in order to realize the organic silicon reagent as reducing agent and amide compounds decarbonylation hydrogenation reaction, is the reduction of amides and derivatives thereof, in particular the organic light-emitting diodes (OLEDs) material unit - diaryl amine compound of the laboratory preparation or industrial production provides a brand-new "green" response strategies. (by machine translation)

One-step synthesis method of iminostilbene

-

Paragraph 0016; 0017; 0018; 0019; 0020; 0021, (2017/05/06)

The invention discloses a one-step synthesis method of iminostilbene, and belongs to the field of drug synthesis. Under the argon protection condition, 2-aminostilbene is added; under the stirring condition, the temperature is slowly increased to 100-105 DEG C, at the moment, 2-aminostilbene is molten, anhydrous phosphorus acid is slowly dropped, after dropping is complete, the temperature is increased to continue the reaction, after the reaction is completed, the product is poured into an ice-water mixture, a 10% sodium hydroxide solution is used for adjusting the pH to be neutral, filtering is performed, a filtrate is extracted through dichloromethane, organic layers are combined and washed three times through saturated salt solutions and water, the organic layers are dried through anhydrous magnesium sulfate, filtering is performed, decompression and rotary evaporation are performed, and dichloromethane is recycled to obtain iminostilbene. According to the method, many defects in the prior art are overcome, iminostilbene can be obtained through the one-step reaction, the yield reaches 95% or above, and a solvent can be recycled. According to the synthesis method of iminostilbene, the iminostilbene synthesis cost can be greatly lowered on the whole, and the industrial application prospect is achieved.

An efficient synthesis for eslicarbazepine acetate, oxcarbazepine, and carbamazepine

Ravinder,Rajeshwar Reddy,Sridhar,Murali Mohan,Srinivas, Katkam,Panasa Reddy,Bandichhor, Rakeshwar

supporting information, p. 2841 - 2844 (2013/06/26)

Efficient methods have been developed for the synthesis of three active pharmaceutical ingredients (APIs) carbamazepine (Tegretol) 1, oxcarbazepine (Trileptal) 2, and eslicarbazepine acetate (Exalief) 3 by employing enantioselective reduction and carboxamidation reaction.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 256-96-2